Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents : A review
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers. HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory diseases, rheumatoid arthritis (RA), etc. Inhibition of HDAC3 metalloenzyme is a dynamic approach for drug design and discovery. This approach has gained considerable interest in recent years. The development of an effective therapeutic agent against HDAC3 is still challenging. A lot of work is still in demand. This current communication is a part of our extended work on HDAC3 inhibitors to achieve deep insight of knowledge about the structural information of HDAC3 inhibitors. This article is unique in terms of detailed structure-activity relationships (SARs) analysis. This may help to find out some important clues to design better active HDAC3 inhibitors in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 192(2020) vom: 15. Apr., Seite 112171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarkar, Rajat [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 30.11.2020 Date Revised 30.11.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2020.112171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307519740 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307519740 | ||
| 003 | DE-627 | ||
| 005 | 20231225125738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2020.112171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307519740 | ||
| 035 | |a (NLM)32163814 | ||
| 035 | |a (PII)S0223-5234(20)30138-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarkar, Rajat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents |b A review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2020 | ||
| 500 | |a Date Revised 30.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers. HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory diseases, rheumatoid arthritis (RA), etc. Inhibition of HDAC3 metalloenzyme is a dynamic approach for drug design and discovery. This approach has gained considerable interest in recent years. The development of an effective therapeutic agent against HDAC3 is still challenging. A lot of work is still in demand. This current communication is a part of our extended work on HDAC3 inhibitors to achieve deep insight of knowledge about the structural information of HDAC3 inhibitors. This article is unique in terms of detailed structure-activity relationships (SARs) analysis. This may help to find out some important clues to design better active HDAC3 inhibitors in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Drug design and discovery | |
| 650 | 4 | |a HDAC3 | |
| 650 | 4 | |a HDAC3 inhibitor | |
| 650 | 4 | |a Metalloenzyme | |
| 650 | 4 | |a SAR | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Histone Deacetylase Inhibitors |2 NLM | |
| 650 | 7 | |a Histone Deacetylases |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a histone deacetylase 3 |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 700 | 1 | |a Banerjee, Suvankar |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Sk Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Adhikari, Nilanjan |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Tarun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 192(2020) vom: 15. Apr., Seite 112171 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:192 |g year:2020 |g day:15 |g month:04 |g pages:112171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2020.112171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 192 |j 2020 |b 15 |c 04 |h 112171 | ||